维奈克拉联合阿扎胞苷治疗强化疗不耐受急性髓细胞白血病患者的临床效果  

Clinical efficacy of venetoclax combined with azacitidine in the treatment of acute myeloid leukemia ineligible for intensive chemotherapy

作　　者：熊红霞[1] 党惠兵[1] 王波涛[1] Xiong Hongxia;Dang Huibing;Wang Botao(Department of Hematology,the First Affiliated Hospital of Nanyang Medical College,Nanyang 473058,China)

机构地区：[1]南阳医学高等专科学校第一附属医院血液内科,南阳473058

出　　处：《中国实用医刊》2024年第5期107-110,共4页Chinese Journal of Practical Medicine

摘　　要：目的探讨维奈克拉联合阿扎胞苷治疗强化疗不耐受急性髓细胞白血病患者的临床效果。方法对照研究。抽取2021年10月至2023年7月南阳医学高等专科学校第一附属医院收治的不耐强化疗急性髓细胞白血病患者80例,按照治疗方案分为对照组和研究组,每组40例。对照组给予阿扎胞苷进行治疗,研究组给予维奈克拉联合阿扎胞苷进行治疗。分析两组患者的一般资料、临床疗效[复合完全缓解(cCR)、总体客观反应率(ORR)]、无事件生存期(EFS)、总生存率(OS)及不良反应事件发生率。结果研究组骨髓原始细胞比例低于对照组(P<0.05),血红蛋白、血小板计数、白细胞计数均高于对照组(P均<0.05)。研究组cCR(70.00%,28/40)、ORR(87.50%,35/40)均高于对照组(42.50%,17/40;65.00%,26/40),P均<0.05。随访中,研究组OS(70.00%,28/40)高于对照组(47.50%,19/40),P<0.05;研究组EFS[10.35(8.75~11.33)个月]大于对照组[7.84(6.95~9.67)个月],P<0.05。两组患者白细胞计数下降、血小板减少、贫血、中性粒细胞减少、感染、胃肠道反应等不良反应事件发生率比较差异均未见统计学意义(P均>0.05)。结论维奈克拉联合阿扎胞苷治疗不耐强化疗急性髓细胞白血病疗效更好,可提高患者复合完全缓解率、总生存率,且不良反应可耐受。Objective To investigate the clinical efficacy of venetoclax combined with azacitidine in the treatment of acute myeloid leukemia ineligible for intensive chemotherapy.Methods A total of 80 patients with acute myeloid leukemia ineligible for intensive chemotherapy admitted to the First Affiliated Hospital of Nanyang Medical College from October 2021 to July 2023 were selected for the controlled study.And they were divided into a control group and a study group according to therapeutic plans,with 40 cases in each group.The control group was treated with azacitidine,and the study group was treated with venetoclax combined with azacitidine.The general data,clinical treatment effect,evaluated by complex complete response(cCR)and overall response rate(ORR),event-free survival(EFS),overall survival(OS),and incidence of adverse events of the two groups were analyzed.Results The proportion of myeloid progenitor cells in the study group was lower than that in the control group(P<0.05),while the hemoglobin,platelet count and white blood cell count in the study group were higher than those in the control group(all P<0.05).The cCR(70.00%,28/40)and ORR(87.50%,35/40)in the study group were higher than those in the control group(42.50%,17/40;65.00%,26/40),all P<0.05.During the follow-up period,the OS of the study group(70.00%,28/40)was higher than that of the control group(47.50%,19/40),P<0.05.The EFS of the study group was 10.35 months(8.75-11.33),higher than the 7.84 months(6.95-9.67)of the control group(P<0.05).There was no significant difference in the incidence of adverse events between the two groups,such as decreased white blood cell count,thrombocytopenia,anemia,neutropenia,infection,and gastrointestinal reactions(all P>0.05).Conclusions Venetoclax combined with azacitidine has a better therapeutic effect in the treatment of acute myeloid leukemia ineligible for intensive chemotherapy.It can improve the cCR and ORR of patients,of which the adverse reactions are tolerable.

关 键 词：白血病 急性 髓细胞 强化疗 不耐受 维奈克拉 阿扎胞苷 治疗效果 

分 类 号：R733.71[医药卫生—肿瘤]